Abstract:Nanomedicines have achieved several successful clinical applications for cancer therapy over the past decades. To date, numerous nanomedicine formats and design rationales have been proposed to improve pharmaceutical delivery and treatment efficacy. Despite these advances, the achievement of high drug loading and loading efficiencies of drug payloads in nanocarriers remains a technical challenge. In addition, study of the correlation between therapeutic potential and drug loading has been ignored. Here, using a self-assembling dimeric cabazitaxel prodrug, we show that the prodrug can be quantitatively entrapped within clinically approved polymer matrices for intravenous injection and that the drug loading in the nanoparticles (NPs) is tunable. The engineered NPs (NPs1-4) with different drug loading values exhibit dissimilar morphologies, release kinetics, in vitro cytotoxic activity, pharmacokinetic properties, tissue distribution, and in vivo anticancer efficacy and safety profiles. Furthermore, the effect of drug loading on the treatment outcomes was explored through detailed in vitro and in vivo studies. Intriguingly, among the constructed NPs, those comprising poly(ethylene glycol)-block-poly(D,L-lactic acid) (PEG-PLA) copolymers showed substantially prolonged pharmacokinetic properties in the blood circulation, which further promoted their intratumoral delivery and accumulation. Furthermore, the PEG-PLA-composed NPs with high drug loading (~50%) demonstrated favorable efficacy and safety profile in animal models. These data provide convincing evidence that the in vivo performance of a given self-assembling drug is not compromised by high drug loading in nanoplatforms, which may potentially reduce concerns over excipient-associated side effects and immunotoxicities. Overall, our study provides new insight into the rationale for designing more effective and less toxic delivery systems.

Vascular disrupting agent-induced amplification of tumor targeting and prodrug activation boosts anti-tumor efficacy

A self-activating nanoized vascular disrupting agent for selective anti-tumor therapy

Platelet-Membrane-Coated Nanoparticles Enable Vascular Disrupting Agent Combining Anti-Angiogenic Drug for Improved Tumor Vessel Impairment.

"Targeted Plus Controlled" - Composite Nano Delivery System Opens the Tumor Vascular and Microenvironment Normalization Window for Anti-Tumor Therapy.

Spatiotemporally Targeted Nanomedicine Overcomes Hypoxia-Induced Drug Resistance of Tumor Cells after Disrupting Neovasculature.

Selective Thrombosis of Tumor for Enhanced Hypoxia-Activated Prodrug Therapy

Vascular Disrupting Agent Induced Aggregation of Gold Nanoparticles for Photothermally Enhanced Tumor Vascular Disruption.

Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents.

A Ph‐responsive Nanoparticle Delivery System Containing Dihydralazine and Doxorubicin‐based Prodrug for Enhancing Antitumor Efficacy

A Dual Drug-Loaded Tumor Vasculature-Targeting Liposome for Tumor Vasculature Disruption and Hypoxia-Enhanced Chemotherapy

Nanodelivery of a Self-Assembling Prodrug with Exceptionally High Drug Loading Potentiates Chemotherapy Efficacy.

Co-delivery of Plinabulin and Tirapazamine boosts anti-tumor efficacy by simultaneously destroying tumor blood vessels and killing tumor cells

Targeting vascular disrupting agent-treated tumor microenvironment with tissue-penetrating nanotherapy

Peptide-IR820 Conjugate: A Promising Strategy for Efficient Vascular Disruption and Hypoxia Induction in Melanoma

Destruction of tumor vasculature by vascular disrupting agents in overcoming the limitation of EPR effect

Platelet-Mimicking Biotaxis Targeting Vasculature-Disrupted Tumors for Cascade Amplification of Hypoxia-Sensitive Therapy

Enhanced Antitumor Efficacy of a Vascular Disrupting Agent Combined with an Antiangiogenic in a Rat Liver Tumor Model Evaluated by Multiparametric MRI

A Tumor Vascular-Targeted Interlocking Trimodal Nanosystem That Induces and Exploits Hypoxia

A Vascular Disrupting Agent Overcomes Tumor Multidrug Resistance by Skewing Macrophage Polarity Toward the M1 Phenotype.

Tumor Vascular Destruction and cGAS‐STING Activation Induced by Single Drug‐Loaded Nano‐Micelles for Multiple Synergistic Therapies of Cancer

Targeting the Tumor Vascular Supply to Enhance Radiation Therapy Administered in Single or Clinically Relevant Fractionated Schedules